Skip to contentE
ENDRA Life Sciences Inc.
E
NDRAENDRA Life Sciences Inc. Q3 2019 · 10-Q
Revenue$0.00$0.00— vs Q3 2018 Net Income-$3.41M-$3.41MN/M vs Q3 2018 EPS Diluted-$0.46-$0.46N/M vs Q3 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
-$2,640,533
N/M
Operating Cash Flowderived-$2,482,729N/M Free Cash Flowderived-$2,482,729N/M ended Sep 30, 2019 · filed Nov 13, 2019 · 44 d after period end